Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study protocol no. VIA-2291-01, a phase 2 randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study of the effect of VIA-2291 on vascular inflammation in patients after an acute coronary syndrome event

Trial Profile

Clinical study protocol no. VIA-2291-01, a phase 2 randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study of the effect of VIA-2291 on vascular inflammation in patients after an acute coronary syndrome event

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Atreleuton (Primary)
  • Indications Acute coronary syndromes
  • Focus Biomarker; Pharmacodynamics
  • Acronyms ACS
  • Sponsors Tallikut Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Mar 2018 Results assessing the change in epicardial fat volume after treatment with atreleuton presented at the 67th Annual Scientific Session of the American College of Cardiology
    • 24 Nov 2016 Results (n=54) assessing the effect of atreleuton on coronary plague progression (serial CT angiography study) published in the Clinical Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top